Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director Peter A. Thompson Sells 1,176,332 Shares

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) Director Peter A. Thompson sold 1,176,332 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $4.16, for a total value of $4,893,541.12. Following the completion of the sale, the director owned 7,165,006 shares in the company, valued at approximately $29,806,424.96. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Corvus Pharmaceuticals Stock Down 1.1%

Shares of CRVS traded down $0.05 during trading on Friday, reaching $3.94. The company's stock had a trading volume of 313,955 shares, compared to its average volume of 827,273. The company has a market cap of $268.25 million, a price-to-earnings ratio of -4.02 and a beta of 0.58. The company has a fifty day moving average of $3.83 and a two-hundred day moving average of $4.24. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.75 and a twelve month high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). As a group, equities analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently modified their holdings of CRVS. Sowell Financial Services LLC acquired a new stake in shares of Corvus Pharmaceuticals in the first quarter valued at approximately $38,000. Virtus ETF Advisers LLC bought a new position in Corvus Pharmaceuticals in the 4th quarter worth approximately $47,000. PKS Advisory Services LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $56,000. Alpine Global Management LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $62,000. Finally, ExodusPoint Capital Management LP bought a new stake in Corvus Pharmaceuticals during the 4th quarter valued at $72,000. Institutional investors own 46.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CRVS. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, May 20th. Oppenheimer reissued an "outperform" rating and issued a $17.00 price objective (up previously from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. Mizuho set a $11.00 price target on shares of Corvus Pharmaceuticals and gave the stock an "outperform" rating in a research report on Tuesday, May 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $15.00.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.